Mode
Text Size
Log in / Sign up
N/A N=269 Randomized Treatment

Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)

Chronic Low-Back Pain · Refractory Pain · Neuropathic Pain

Enrolled (actual)
269
Serious AEs
2.6%
Results posted
Jun 2024
Primary outcome: Primary: The Difference in Responders Between Both Groups — 87; 5 participants — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Spinal Cord Stimulation (Device); Conventional Medical Management (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abbott Medical Devices
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
The Difference in Responders Between Both Groups
87; 5 <0.0001 sig
SECONDARY
Measure of Composite Responder Rate
93; 13 < 0.0001 sig
SECONDARY
Numerical Rating Scale (NRS) Relative Change From Baseline to 6 Months
69.7; 5.6 <0.0001 sig
SECONDARY
Oswestry Disability Index (ODI) Change From Baseline to 6 Months
29.4; 0.7 <0.0001 sig
SECONDARY
Pain Catastrophizing Scale (PCS) Responder Rate
90; 19 <0.0001 sig
SECONDARY
Patient Global Impression of Change (PGIC) Responder Rate
77; 2 <0.0001 sig
SECONDARY
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months
17.9; 0.9 <0.0001 sig
SECONDARY
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months
27.8; 1.4 <0.0001 sig

Summary

The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic, refractory axial low back pain with a neuropathic component, who have not had lumbar spine surgery and for whom surgery is not an option.

Eligibility Criteria

Inclusion Criteria

  • Patient must be willing and able to provide written informed consent prior to any clinical investigation-related procedure.
  • Age ≥ 18 years
  • Patient has chronic (at least 6 months), refractory axial low back pain with a neuropathic component and is not a candidate for spine surgery
  • Patient has back pain for ≥ 6 months inadequately responsive to supervised conservative care
  • Patient has not had spine surgery for back or leg pain
  • Patient is a candidate for spinal cord stimulation
  • Low back pain ≥ 6 on Numerical Rating Scale
  • Oswestry Disability Index score of ≥ 30%
  • Willing and able to comply with the instructions for use, operate the study device, and comply with this Clinical Investigation Plan

Exclusion Criteria

  • Pathology seen on imaging tests obtained within the past 12 months that is clearly identified and is likely the cause of the CLBP, that can be addressed with surgery.
  • Primary complaint of leg pain, or leg pain is greater than back pain
  • Back pain is due to any of the following:
  • spinal instability defined as > 2 mm translation on radiographic imaging
  • visceral causes (e.g., endometriosis or fibroids)
  • vascular causes (e.g., aortic aneurysm)
  • spinal infection (e.g., osteomyelitis)
  • inflammation or damage to the spinal cord (e.g. arachnoiditis or syringomyelia)
  • tumor or spinal metastases
  • Has widespread pain (e.g. fibromyalgia) or pain in other area(s), not intended to be treated in this study (e.g. neck pain, shoulder pain)
  • Patient has seronegative spondyloarthropathy (e.g. rheumatoid, lupus, psoriatic)
  • Neurological deficit (e.g. foot drop)
  • Prior lumbar spine surgery or sacroiliac joint fusion
  • Patient has used a morphine equivalent daily dose of more than 50 MME in the last 30 days
  • Patient is bed bound
  • Patients with regular intake of systemic steroids (except inhaled steroids used to treat asthma)
  • Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicates lead placement
  • Known allergic reaction to implanted materials
  • Severe scoliotic deformity (>11 degrees in thoracic or lumbar spine)
  • Patient has a history of, or existing intrathecal drug pump
  • Patient has previous experience with neuromodulation devices, including a failed trial
  • BMI > 40
  • Patient is enrolled, or intends to participate, in another clinical drug and/or device study or registry that may interfere with the results of this study, as determined by Abbott personnel
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.
  • Failed psychological evaluation
  • Suspicion or evidence of untreated mental illness, or substance abuse
  • Patient demonstrated 2 or more Waddell's signs of nonorganic behavior
  • Patient is in current litigation for back pain/injury, or is currently receiving worker's compensation
  • Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.
  • Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to enrollment/baseline visit per site standard test.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04479787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search